Carcinoid syndrome represents a debilitating paraneoplastic disease, caused by the se- cretion of several substances, occurring in about 10–40% of patients with well-differentiated neu- roendocrine tumors (NETs). The main signs and symptoms associated with carcinoid syndrome are flushing, diarrhea, hypotension, tachycardia, bronchoconstriction, venous telangiectasia, dyspnea and fibrotic complications (mesenteric and retroperitoneal fibrosis, and carcinoid heart disease). Although there are several drugs available for the treatment of carcinoid syndrome, the lack of therapeutic response, poor tolerance or resistance to drugs are often reported. Preclinical models are indispensable tools for investigating the pathogenesis, mechanisms for tumor progression and new therapeutic approaches for cancer. This paper provides a state-of-the-art overview of in vitro and in vivo models in NETs with carcinoid syndrome, highlighting the future developments and therapeutic approaches in this field.

Carcinoid Syndrome. Preclinical Models and Future Therapeutic Strategies / Vitale, Giovanni; Carra, Silvia; Alessi, Ylenia; Campolo, Federica; Pandozzi, Carla; Zanata, Isabella; Colao, Annamaria; Faggiano, Antongiulio. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:4(2023), pp. 1-22. [10.3390/ijms24043610]

Carcinoid Syndrome. Preclinical Models and Future Therapeutic Strategies

Giovanni Vitale
;
Federica Campolo;Carla Pandozzi;Antongiulio Faggiano
2023

Abstract

Carcinoid syndrome represents a debilitating paraneoplastic disease, caused by the se- cretion of several substances, occurring in about 10–40% of patients with well-differentiated neu- roendocrine tumors (NETs). The main signs and symptoms associated with carcinoid syndrome are flushing, diarrhea, hypotension, tachycardia, bronchoconstriction, venous telangiectasia, dyspnea and fibrotic complications (mesenteric and retroperitoneal fibrosis, and carcinoid heart disease). Although there are several drugs available for the treatment of carcinoid syndrome, the lack of therapeutic response, poor tolerance or resistance to drugs are often reported. Preclinical models are indispensable tools for investigating the pathogenesis, mechanisms for tumor progression and new therapeutic approaches for cancer. This paper provides a state-of-the-art overview of in vitro and in vivo models in NETs with carcinoid syndrome, highlighting the future developments and therapeutic approaches in this field.
2023
carcinoid syndrome; preclinical models; neuroendocrine tumors; serotonin; xenograft; pharmacological treatment
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Carcinoid Syndrome. Preclinical Models and Future Therapeutic Strategies / Vitale, Giovanni; Carra, Silvia; Alessi, Ylenia; Campolo, Federica; Pandozzi, Carla; Zanata, Isabella; Colao, Annamaria; Faggiano, Antongiulio. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 24:4(2023), pp. 1-22. [10.3390/ijms24043610]
File allegati a questo prodotto
File Dimensione Formato  
Vitale_Carcinoid-Syndrome_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2 MB
Formato Adobe PDF
2 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1671000
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact